

World Alzheimer Report 2009

APPENDIX 1

Global Burden of Disease (GBD) regions

Regions for which meta-analysis could be performed.

GBD Region	Countries (those with one or more studies <u>underlined</u>)	Relationship to WHO regions used for <i>Lancet</i>/ADI estimates	Approach used to generate regional prevalence and numbers
ASIA			
Australasia	<u>Australia</u> , <u>New Zealand</u>	WPRO A	Apply estimates from meta-analysis.
Asia Pacific, High Income	Brunei, <u>Japan</u> , <u>Republic of Korea</u> , <u>Singapore</u>	WPRO A except for Korea (WPRO B)	Apply estimates from meta-analysis.
Asia, East	<u>China</u> , Democratic People's Republic of Korea, <u>Hong Kong</u> , <u>Chinese Taipei</u>	WPRO B except for Democratic People's Republic of Korea (SEARO D)	Apply estimates from meta-analysis.
Asia, South	Afghanistan, Bangladesh, Bhutan, <u>India</u> , Nepal, Pakistan	SEARO D except for Afghanistan and Pakistan (EMRO D)	Apply estimates from meta-analysis.
Asia, Southeast	Cambodia, Indonesia, Laos, <u>Malaysia</u> , Maldives, Mauritius, Mayotte, Myanmar, Philippines, Seychelles, <u>Sri Lanka</u> , <u>Thailand</u> , Timore Leste, Viet Nam	Mainly SEARO B and WPRO B.	Apply estimates from meta-analysis.
EUROPE			
Europe, Western	Andorra, Austria, <u>Belgium</u> , Channel Islands, Cyprus, <u>Denmark</u> , Faeroe Islands, <u>Finland</u> , <u>France</u> , <u>Germany</u> , Gibraltar, Greece, Greenland, Holy See, Iceland, Ireland, Isle of Man, <u>Israel</u> , <u>Italy</u> , Liechtenstein, Luxembourg, Malta, Monaco, <u>Netherlands</u> , <u>Norway</u> , Portugal, Saint Pierre et Miquelon, <u>San Marino</u> , <u>Spain</u> , <u>Sweden</u> , <u>Switzerland</u> , <u>United Kingdom</u>	EURO A	Apply estimates from meta-analysis.
THE AMERICAS			
North America	<u>Canada</u> , <u>United States of America</u>	AMRO A	Conduct meta-analysis for USA. Apply CSHA data for Canada, then

			aggregate
Latin America, Andean	Bolivia, Ecuador, <u>Peru</u>	AMRO D	Apply estimates from meta-analysis conducted across all four regions
Latin America, Central	Colombia, Costa Rica, El Salvador, Guatemala, Honduras, <u>Mexico</u> , Nicaragua, Panama, <u>Venezuela</u>	AMRO B except for Guatemala and Nicaragua (AMRO D)	
Latin America, Southern	Argentina, <u>Chile</u> , Falkland Islands (Malvinas), Uruguay	AMRO B	
Latin America, Tropical	<u>Brazil</u> , Paraguay	AMRO B	

Regions for which meta-analysis could not be performed.

GBD Region	Countries (those with one or more studies <u>underlined</u>)	Relationship to WHO regions used in <i>Lancet</i>/ADI	Approach
ASIA			
Asia, Central	Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan	EURO B, except for Kazakhstan (EURO C)	Apply relevant <i>Lancet</i> /ADI estimates to each country and aggregate
Oceania	American Samoa, Cook Islands, Fiji, French Polynesia, <u>Guam</u> , Kiribati, Marshall Islands, Micronesia (Federated States of), Nauru, New Caledonia, Niue, Northern Mariana Islands, Palau, Papua New Guinea, Pitcairn, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna Islands	WPRO B	Data from one study in Guam only (indigenous Chamorros islanders). Therefore use <i>Lancet</i> /ADI WPRO B for all countries
EUROPE			
Europe, Central	Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, <u>Poland</u> , Romania, Serbia and Montenegro, Slovakia, Slovenia, The Former Yugoslav Republic of Macedonia	EURO B, except for Croatia, Czech Republic and Slovenia (EURO A)	Apply relevant <i>Lancet</i> /ADI estimates to each country and aggregate
Europe, Eastern	Belarus, Estonia, Latvia, Lithuania, Republic of Moldova, <u>Russian Federation</u> , Ukraine	EURO C	Apply <i>Lancet</i> /ADI EURO C estimates
THE AMERICAS			
Caribbean	Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados,	AMRO B, other than Haiti (AMRO D) and	Use 10/66 Cuba and Dominican

	Belize, Bermuda, British Virgin Islands, Cayman Islands, <u>Cuba</u> , Dominica, <u>Dominican Republic</u> , French Guiana, Grenada, Guadeloupe, Guyana, Haiti, Jamaica, Martinique, Montserrat, Netherlands Antilles, Saint Kitts and Nevis, St. Lucia, St. Vincent, Suriname, Trinidad and Tobago, Turks and Caicos Islands	Cuba (AMRO A)	Republic prevalence for those countries. Apply relevant <i>Lancet</i> /ADI estimates to other countries and aggregate
AFRICA			
North Africa / Middle East	Algeria, Bahrain, <u>Egypt</u> , Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territory, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, <u>Turkey</u> , United Arab Emirates, Western Sahara, Yemen	EMRO B, except for Egypt, Iraq, Morocco and Yemen (EMRO D), Algeria (AFRO D) and Turkey (EURO B)	Apply Turkey study estimates to Turkey. Apply Egypt study estimates to Egypt and other EMRO D countries. Apply relevant <i>Lancet</i> /ADI estimates to other countries and aggregate
Sub-Saharan Africa, Central	Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon	A mixture of AFRO D and AFRO E	Apply relevant <i>Lancet</i> /ADI estimates to each country and aggregate
Sub-Saharan Africa, East	Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, Sudan, Uganda, United Republic of Tanzania, Zambia	AFRO E except for Comoros (AFRO D) and Somalia and Sudan (EMRO D)	Apply relevant <i>Lancet</i> /ADI estimates to each country and aggregate
Sub-Saharan Africa, Southern	Botswana, Lesotho, Namibia, <u>South Africa</u> , Swaziland, Zimbabwe	AFRO E	Apply <i>Lancet</i> / ADI AFRO E estimates
Sub-Saharan Africa, West	Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Cote d'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, <u>Nigeria</u> , Saint Helena, Sao Tome and Principe, Senegal, Sierra Leone, Togo	AFRO D	Apply Nigeria (Hendrie) prevalence estimates to all countries in this region